Savara, Inc. (SVRA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$4.38-6.01%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · SVRA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name is on a run of consecutive earnings misses and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
SVRA — officer change
Dated 2026-06-08
Chief Financial and Operating Officer — Robert Lutz: Robert Lutz was promoted to Chief Financial and Operating Officer, succeeding David Lowrance who resigned due to health reasons.
Why it matters: The company planned to move into leased office space on July 1. A confirmed move would complete this stated priority.
Supportive ifSVRA confirms it moved into the leased office space after July 1, 2026.
Worry ifSVRA reports that it has not moved in or that the office opening was delayed.
Why it matters: Robert Lutz took both roles in June 2026. Later reports can show whether losses improve or worsen under the new leadership.
Watch forA later report shows operating and net losses below the 2026-Q2 levels of $40.9 million and $40.2 million.
Also watch forA later report shows operating loss above $40.9 million or net loss above $40.2 million.
Why it matters: The loan is a stated funding priority, while losses grew in the periods cited. A smaller loss would show progress; a larger loss would show the pressure continues.
Watch forA later report shows operating loss below $40.9 million and net loss below $40.2 million. These were the 2026-Q2 levels cited.
Also watch forA later report shows operating loss above $40.9 million or net loss above $40.2 million.
Why it matters: SVRA reported losses in the periods cited, and its current signals show ongoing losses. The report can show whether losses are narrowing or widening.
Watch forThe report shows operating loss below $40.9 million and net loss below $40.2 million. These are below 2026-Q2 levels.
Also watch forThe report shows operating loss above $40.9 million or net loss above $40.2 million.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$186 on $10,000 · ±1.9% | How much price usually moves either way. |
| Bad day | $504 loss on $10,000 · 5.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,919 loss on $10,000 · 39.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Approval by this date triggers a $75 million payment. A delay or rejection would put that payment at risk.
Supportive ifFDA approves MOLBREEVI by March 31, 2027. This triggers the $75 million payment.
Worry ifFDA does not approve MOLBREEVI by March 31, 2027, or rejects the application.